BioCentury
ARTICLE | Clinical News

CMV alphavaccine: Phase I data

April 21, 2008 7:00 AM UTC

Initial data from a double-blind, placebo-controlled, U.S. Phase I trial (AVX601-001) in 40 healthy volunteers showed that AVX601 was safe and well tolerated. Most volunteers developed antibody or T c...